With the Roche’s acquisition of Genentech finalized the next obvious set of question surrounds who stays and who goes.
More specifically, does somebody like CEO Art Levinson, arguably the singular driving force since 1995 – albeit playing the point on an executive group that behaves from a distance like a real team – stay?
The quick answer is not likely .… Read the rest